Keyword Analysis & Research: ddavp uremic bleeding

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
ddavp uremic bleeding0.240.994955921
ddavp0.760.89816215
uremic1.190.87304966
bleeding0.80.62283978

Keyword Research: People who searched ddavp uremic bleeding also searched

Keyword CPC PCC Volume Score
ddavp uremic bleeding0.60.3842471
ddavp uremic bleeding dose0.140.2401351
ddavp dosing uremic bleeding1.570.7973984
ddavp for uremic bleeding1.190.3567852
ddavp dose for bleeding1.290.2903627
ddavp dosing for bleeding0.110.1163810
ddavp for surgical bleeding0.30.540241
ddavp use in bleeding0.740.9837973
ddavp in bleeding patients1.790.9728687
ddavp for uremic platelets1.40.7438022
ddavp for uremic platelet dysfunction1.230.5489082
ddavp medication for bleeding1.950.3549949
ddavp for bleeding in renal failure0.150.4194866
why is ddavp treatment for uremia1.610.2901866
dose of ddavp for di0.551235686
ddavp for bleeding side effects0.580.2541618
ddavp dose for platelet dysfunction1.380.397329
ddavp for gi bleed1.750.3667285
ddavp dosing for di1.660.9549986

Search Results related to ddavp uremic bleeding on Search Engine

  • Ddavp Online

    ddavpinfo.com

    https://ddavpinfo.com/

    WEBCommon uses of Ddavp include managing bedwetting (nocturnal enuresis) in children and adults, treating central diabetes insipidus (a condition that causes excessive thirst and urination), and controlling bleeding disorders such …

    DA: 31 PA: 100 MOZ Rank: 55

  • Uremic platelet dysfunction - UpToDate

    uptodate.com

    https://www.uptodate.com/contents/uremic-platelet-dysfunction

    WEBApr 6, 2023 · Impaired platelet function is one of the main determinants of abnormal bleeding in patients with a low glomerular filtration rate (GFR). Although often referred to as "uremic bleeding," bleeding in this setting generally occurs in patients who do not have clinical symptoms or signs of uremia.

    DA: 19 PA: 19 MOZ Rank: 52

  • Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: …

    ashpublications.org

    https://ashpublications.org/blood/article/90/7/2515/238641/Desmopressin-DDAVP-in-the-Treatment-of-Bleeding

    WEBOct 1, 1997 · The hemostatic defect in uremia is characterized by a prolonged bleeding time, a laboratory abnormality that correlates strongly with the hemorrhagic symptoms of these patients, mainly epistaxis and bleeding from the gastrointestinal tract.

    DA: 38 PA: 2 MOZ Rank: 28

  • 15. Uremic Bleeding | Hospital Handbook

    ucsf.edu

    https://hospitalhandbook.ucsf.edu/content/15-uremic-bleeding

    WEBDDAVP 0.3 mcg/kg IV q12 hours x 2 doses (tachyphylaxis typically occurs after 2 doses). This is the most rapid therapy. Conjugated estrogen 0.6 mg/kg IV Qday x 5 days (if persistent bleeding after dialysis, DDAVP). The duration of …

    DA: 9 PA: 10 MOZ Rank: 9

  • Evidence-based treatment recommendations for uremic bleeding

    nature.com

    https://www.nature.com/articles/ncpneph0421

    WEBThe most common agent used in uremic patients with active bleeding is desmopressin (1-deamino-8-D-arginine vasopressin [DDAVP]). It is predominately used to treat diabetes...

    DA: 67 PA: 49 MOZ Rank: 45

  • Evidence-based treatment recommendations for uremic …

    nature.com

    https://www.nature.com/articles/ncpneph0421.pdf

    WEBUremic bleeding syndrome is a recognized consequence of renal failure and can result in clinically significant sequelae. Although the pathophysiology of the condition has yet to be fully...

    DA: 48 PA: 63 MOZ Rank: 34

  • Evidence-Based Treatment Recommendations for Uremic Bleeding

    medscape.com

    https://www.medscape.com/viewarticle/553187_7

    WEBAbbreviations: DDAVP, desmopression (1-deamino-8-D-arginine vasopressin; single doses of 0.3–0.4 μg/kg body weight intravenous); EPO, erythropoietin. Should a Hemodynamically Stable,...

    DA: 52 PA: 69 MOZ Rank: 22

  • Uremic platelet dysfunction - UpToDate

    uptodate.com

    https://www.uptodate.com/contents/uremic-platelet-dysfunction/print

    WEBDec 2, 2022 · Although often referred to as "uremic bleeding," bleeding in this setting generally occurs in patients who do not have clinical symptoms or signs of uremia.

    DA: 9 PA: 29 MOZ Rank: 9

  • Chronic and End-Stage Kidney Disease in the ... - ScienceDirect

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S1052305721002226

    WEBSep 1, 2021 · Uremia affects intrinsic platelet function by blocking multiple pathways important for platelet aggregation and cross-linking, interfering with platelet-vessel wall interactions, and increasing nitric oxide production. 23 Hemodialysis procedures and use of anticoagulation can increase bleeding risk, and many underlying conditions that …

    DA: 14 PA: 55 MOZ Rank: 31

  • Effect of Deamino-8-D-Arginine Desmopressin in Uremic Bleeding

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532022/

    WEBNov 2, 1996 · Conjugated estrogen 19,20) and DDAVP (desmopressin, 1-deamino-8-D-arginine vasopressin) 21,22) were introduced as an alternative to cryoprecipitate in uremic bleeding. DDAVP induces the release of factor VIII and von Willebrand factor (vWF) from storage site into plasma 23).

    DA: 56 PA: 64 MOZ Rank: 87

  • Thrombosis following desmopressin for uremic bleeding

    wiley.com

    https://onlinelibrary.wiley.com/doi/10.1002/ajh.2830280115

    WEBAn elderly patient with evidence of atherosclerosis and uremic bleeding diathesis developed two foci of cerebral thrombosis immediately after an infusion of desmopressin (DDAVP).

    DA: 18 PA: 95 MOZ Rank: 83

  • Safety of renal biopsy bleeding prophylaxis with desmopressin

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489756/

    WEBSep 30, 2021 · Therefore, a single intravenous dose of DDAVP adjusted to patient’s weight is safe as a bleeding prophylaxis pre-PRB and may be used in patients with a higher risk of haemorrhagic complications, such as those with uraemia …

    DA: 23 PA: 17 MOZ Rank: 20

  • Uremic bleeding syndrome - WikEM

    wikem.org

    https://wikem.org/wiki/Uremic_bleeding_syndrome

    WEBBackground. Bleeding diathesis. Increased risk for of bleeding ( GI, ICH, liver hematoma) due to impaired platelet function. Uremic toxins inhibit platelet aggregation. Disrupts vWF. PT/PTT normal, but bleeding time elevated. Clinical Features. Wide range of presentations. Ecchymosis, purpura, epistaxis, fistula bleeding, venipuncture bleeding.

    DA: 90 PA: 43 MOZ Rank: 79

  • Desmopressin - StatPearls - NCBI Bookshelf

    nih.gov

    https://www.ncbi.nlm.nih.gov/books/NBK554582/

    WEBJun 22, 2023 · Desmopressin (1-deamino-8-D-arginine vasopressin) is a synthetic analog of vasopressin, aka antidiuretic hormone, created in 1977 and used in the treatment of a wide variety of medical conditions including nocturnal polyuria, hemophilia A, diabetes insipidus, Willebrand disease, uremic bleeding, as well as many off label uses such as …

    DA: 55 PA: 20 MOZ Rank: 48

  • Ddavp for Hemorrhage in Esrd Patients – Sinai EM

    sinaiem.org

    https://sinaiem.org/foam/ddavp-for-hemorrhage-in-esrd-patients/

    WEBSep 5, 2014 · There is data to support giving DDAVP to a patient with platelet dysfunction associated with ESRD or “uremic bleeding”. Unfortunately, the data inform us from trials of patients who are clinically uremic, which as a clinical diagnosis distinct from a laboratory diagnosis of azotemia.

    DA: 26 PA: 13 MOZ Rank: 75

  • DDAVP, Stimate (desmopressin) dosing, indications, interactions

    medscape.com

    https://reference.medscape.com/drug/ddavp-stimate-noctiva-desmopressin-342819

    WEBUremic Bleeding in Acute or Chronic Renal Failure. 0.4 mcg/kg IV over 10 minutes . Dosing Modifications Renal impairment. CrCl ; 50 mL/min: Contraindicated; has been used unlabeled in acute and chronic renal failure patients experiencing uremic bleeding or prevention of surgical bleeding CrCl ≥50 mL/min: No adjustments necessary; Dosing ...

    DA: 74 PA: 37 MOZ Rank: 14

  • Desmopressin improves platelet function in uremic patients ... - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/25933676/

    WEBPMID: 25933676. DOI: 10.1007/s00277-015-2384-1. Abstract. Uremia is associated with platelet dysfunction and can cause a bleeding tendency resulting in a major bleeding event after an invasive procedure or surgery that may be aggravated by antiplatelet agents.

    DA: 87 PA: 11 MOZ Rank: 70

  • Safety of renal biopsy bleeding prophylaxis with desmopressin

    sagepub.com

    https://journals.sagepub.com/doi/full/10.1177/03000605211040764

    WEBSep 30, 2021 · Percutaneous renal biopsy (PRB) is invasive, and bleeding-related complications are a concern. Desmopressin (DDAVP) is a selective type 2 vasopressin receptor-agonist also used for haemostasis. Aim. To evaluate the side effects of intravenous (IV) weight-adjusted desmopressin preceding PRB. Methods.

    DA: 79 PA: 23 MOZ Rank: 76

  • Renal biopsy practice: What is the gold standard? - PMC

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220363/

    WEBNov 6, 2014 · Renal biopsy (RB) is useful for diagnosis and therapy guidance of renal diseases but incurs a risk of bleeding complications of variable severity, from transitory haematuria or asymptomatic hematoma to life-threatening hemorrhage.

    DA: 61 PA: 76 MOZ Rank: 31

  • Low-dose intranasal desmopressin (DDAVP) for uremic bleeding

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/9031290/

    WEBLow-dose intranasal desmopressin (DDAVP) for uremic bleeding. . Nephron. 1997;75(1):119-20.doi: 10.1159/000189519. Authors. . S Ozen, U Saatci, A Bakkaloglu, S Ozdemir, O Ozdemir, N Besbas. PMID: . 9031290. . DOI: . 10.1159/000189519. . No abstract available. Publication types. . Letter. .

    DA: 77 PA: 15 MOZ Rank: 48

  • How do you treat bleeding disorders with desmopressin? - PMC

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2599976/

    WEBAug 5, 2006 · Use of desmopressin in the treatment of bleeding disorders. Desmopressin has been successfully used in the prophylaxis and treatment of bleeding episodes in some patients with VWD types 1 and 2, mild to moderate haemophilia A, platelet function defects related to aspirin use, uraemia and inherited platelet disorders, bleeding related to ...

    DA: 5 PA: 9 MOZ Rank: 27

  • Understanding Uremia - U.S. Pharmacist

    uspharmacist.com

    https://www.uspharmacist.com/article/understanding-uremia-42384

    WEBAug 20, 2013 · Management of Uremic Bleeding. Patients with uremic bleeding may present with various symptoms of bleeding (e.g., epistaxis, ecchymosis), as well as mild thrombocytopenia. 10 Other causes of bleeding must be ruled out prior to formulating a therapeutic plan for uremic patients. Bleeding time is considered to be the preferred test …

    DA: 67 PA: 81 MOZ Rank: 72

  • Desmopressin acetate (DDAVP) for preventing and treating acute …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373982/

    WEBFeb 13, 2019 · Desmopressin acetate (DDAVP) is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects of DDAVP in these groups of pregnant women should be evaluated.

    DA: 97 PA: 11 MOZ Rank: 50